These controversial results of MR16-1 treatment on mdx mice hinder the use of IL-6R antagonists for the treatment of DMD patients, and it is therefore necessary to perform further studies to clarify the effects. This evidence concerns the gene IL6R and Duchenne muscular dystrophy.